LAT-8881(LAT-8881) - 药物靶点：GHR_在研适应症：糖尿病性神经病变，腰椎神经根病，根性疼痛_专利_临床

概要

基本信息

药物类型

化学药

别名

靶点

GHR

作用机制

GHR激动剂(生长激素受体激动剂)

治疗领域

神经系统疾病内分泌与代谢疾病其他疾病

在研适应症

糖尿病性神经病变腰椎神经根病根性疼痛

非在研适应症

急性偏头痛糖尿病周围神经病变疱疹后神经痛+ [2]

原研机构

Mesoestetic Sl

在研机构

Lateral Pharma Pty Ltd.

非在研机构

Metabolic Pharmaceuticals Pty Ltd.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C78H123N23O23S2

InChIKeyGVIYUKXRXPXMQM-BPXGDYAESA-N

CAS号221231-10-3

序列信息

Sequence Code 86160

关联

5

项与 LAT-8881 相关的临床试验

NCT05298306 / Completed临床1期

A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain

The study consists of two parts. Part A will evaluate the safety and tolerability of intravenous LAT8881 in healthy volunteers using an ascending dose schedule. Part B will evaluate the analgesic efficacy of a single intravenous dose of LAT8881, compared with placebo, in patients with lumbar radicular pain.
Healthy volunteers are not accepted for Part B.

开始日期2022-05-17

申办/合作机构

Lateral Pharma Pty Ltd.

[+1]

ACTRN12619001369112 / Completed临床2期

A proof of concept study of the efficacy and safety of oral LAT8881 in acute migraine

开始日期2019-10-04

申办/合作机构

Lateral Pharma Pty Ltd.

NCT04153409 / Completed临床2期

A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine

This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.

开始日期2019-09-24

申办/合作机构

Lateral Pharma Pty Ltd.

100 项与 LAT-8881 相关的临床结果

登录后查看更多信息

100 项与 LAT-8881 相关的转化医学

登录后查看更多信息

100 项与 LAT-8881 相关的专利（医药）

登录后查看更多信息

15

项与 LAT-8881 相关的文献（医药）

2024-08-16·The Journal of Infectious Diseases

Harnessing Endogenous Peptide Compounds as Potential Therapeutics for Severe Influenza

Article

作者: Tate, Michelle D ; Ely, Lauren K ; Hodges, Christopher ; West, Alison C ; Harpur, Christopher M ; Lam, Maggie ; Le Page, Mélanie A ; Gearing, Andrew J

AbstractBackgroundExcessive pulmonary inflammation and damage are characteristic features of severe influenza virus infections. LAT8881 is a synthetic 16–amino acid cyclic peptide form of a naturally occurring C-terminal fragment of human growth hormone with therapeutic efficacy against influenza. Shorter linear peptides are typically easier to manufacture and formulate for delivery than larger cyclic peptides. A 6–amino acid linear peptide fragment of LAT8881, LAT9997, was investigated as a potential influenza therapy.MethodsLAT9997 was evaluated for its potential to limit disease in a preclinical mouse model of severe influenza infection.ResultsIntranasal treatment of mice with either LAT8881 or LAT9997 from day 1 following influenza infection significantly improved survival outcomes. Initiating LAT9997 treatment at the onset of severe disease also significantly improved disease severity. Greater disease resistance in LAT9997-treated mice correlated with reduced lung immunopathology, damage markers, vascular leak, and epithelial cell death. Treatment reduced viral loads, cytokines, and neutrophil infiltration in the airways yet maintained protective alveolar macrophages in a dose-dependent manner. Sequential trimming of N- and C-terminal amino acids from LAT9997 revealed a structure-activity relationship.ConclusionsThese findings provide preclinical evidence that therapeutic LAT9997 treatment limits viral burden and characteristic features of severe influenza, including hyperinflammation and lung damage.SummaryExcessive pulmonary inflammation and damage are characteristic features of severe influenza virus infections. LAT9997 is a linear peptide fragment derived from human growth hormone. This study provides preclinical evidence that therapeutic LAT9997 treatment limits viral burden, hyperinflammation, and lung damage.

2023-01-01·Clinical & translational immunology

Naturally derived cytokine peptides limit virus replication and severe disease during influenza A virus infection.

Article

作者: Tate, Michelle D ; Harpur, Christopher M ; Hodges, Christopher ; Oseghale, Osezua ; Lam, Maggie ; Le Page, Mélanie A ; West, Alison C ; Gearing, Andrew J

ObjectivesNovel host-targeted therapeutics could treat severe influenza A virus (IAV) infections, with reduced risk of drug resistance. LAT8881 is a synthetic form of the naturally occurring C-terminal fragment of human growth hormone. Acting independently of the growth hormone receptor, it can reduce inflammation-induced damage and promote tissue repair in an animal model of osteoarthritis. LAT8881 has been assessed in clinical trials for the treatment of obesity and neuropathy and has an excellent safety profile. We investigated the potential for LAT8881, its metabolite LAT9991F and LAT7771 derived from prolactin, a growth hormone structural homologue, to treat severe IAV infection.MethodsLAT8881, LAT9991F and LAT7771 were evaluated for their effects on cell viability and IAV replication in vitro, as well as their potential to limit disease in a preclinical mouse model of severe IAV infection.ResultsIn vitro LAT8881 treatment enhanced cell viability, particularly in the presence of cytotoxic stress, which was countered by siRNA inhibition of host lanthionine synthetase C-like proteins. Daily intranasal treatment of mice with LAT8881 or LAT9991F, but not LAT7771, from day 1 postinfection significantly improved influenza disease resistance, which was associated with reduced infectious viral loads, reduced pro-inflammatory cytokines and increased abundance of protective alveolar macrophages. LAT8881 treatment in combination with the antiviral oseltamivir phosphate led to more pronounced reduction in markers of disease severity than treatment with either compound alone.ConclusionThese studies provide the first evidence identifying LAT8881 and LAT9991F as novel host-protective therapies that improve survival, limit viral replication, reduce local inflammation and curtail tissue damage during severe IAV infection. Evaluation of LAT8881 and LAT9991F in other infectious and inflammatory conditions of the airways is warranted.

2015-01-01·Drug Testing and Analysis2区 · 医学

Detection and in vitro metabolism of AOD9604

2区 · 医学

Article

作者: Cox, Holly D. ; Smeal, Stacy J. ; Hughes, Cole M. ; Cox, James E. ; Eichner, Daniel

AOD9604 is a peptide consisting of the C‐terminal fragment of human growth hormone from amino acids 177–191 with an additional tyrosine residue at the N‐terminus of the peptide. It is reported to mimic the lipolytic properties of growth hormone without the diabetogenic side effects. Therefore, AOD9604 may be used as a performance enhancing drug and is banned by the World Anti‐doping Agency (WADA). The peptide is available on several Internet websites and was recently identified in confiscated vials in the USA. To detect abuse of the peptide in athletes, a solid‐phase extraction method was validated in urine with a limit of detection of 50 pg/mL. The method has good linearity, precision (<20%), specificity and recovery (62%). Six potential metabolites of the peptide were identified after incubation of AOD9604 in serum and urine. Quantification of the metabolites in serum identified a single metabolite, consisting of amino acids CRSVEGSCG, which is significantly more stable than the other metabolites or the parent compound. Screening for AOD9604 and the stable metabolite may potentially allow an increased window of detection. Copyright © 2014 John Wiley & Sons, Ltd.

100 项与 LAT-8881 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性偏头痛	临床2期	澳大利亚	Lateral Pharma Pty Ltd.	2019-09-24
糖尿病周围神经病变	临床2期	英国	Lateral Pharma Pty Ltd.	2019-04-09
糖尿病周围神经病变	临床2期	澳大利亚	Lateral Pharma Pty Ltd.	2019-04-09
疱疹后神经痛	临床2期	英国	Lateral Pharma Pty Ltd.	2019-04-09
疱疹后神经痛	临床2期	澳大利亚	Lateral Pharma Pty Ltd.	2019-04-09
糖尿病性神经病变	临床2期	-	-	-
肥胖	临床2期	澳大利亚	Metabolic Pharmaceuticals Pty Ltd.	-
骨质疏松症	临床2期	澳大利亚	-	-
腰椎神经根病	临床1期	澳大利亚	Lateral Pharma Pty Ltd.	2022-05-17
根性疼痛	临床1期	澳大利亚	Lateral Pharma Pty Ltd.	2022-05-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03865953 (CTgov)	临床2期	疱疹后神经痛 \| 糖尿病周围神经病变	53	LAT8881 (LAT8881)	廠構淵範餘網鏇獵廠顧(廠築鏇製餘廠憲鏇選齋) = 簾願餘願網構鏇製製築壓製餘觸選範膚簾糧製 (鏇窪鹹鬱膚顧醖選構餘, 餘築齋顧網淵鏇糧選衊 ~ 窪壓顧鹽願淵鏇獵選顧) 更多	-	2021-04-23
				Placebo (Placebo)	廠構淵範餘網鏇獵廠顧(廠築鏇製餘廠憲鏇選齋) = 夢醖艱醖衊築築鹽遞願壓製餘觸選範膚簾糧製 (鏇窪鹹鬱膚顧醖選構餘, 糧廠窪繭簾網齋鑰齋獵 ~ 繭選壓衊顧夢壓觸觸襯) 更多
NCT04153409 (CTgov)	临床2期	急性偏头痛	21	LAT8881 (Active)	窪願繭餘築艱獵壓繭遞(構網窪糧鏇網鹹網壓壓) = 鏇願夢襯積壓糧鹽廠獵夢願醖鏇淵壓齋鏇窪廠 (製窪糧襯範選夢鬱膚製, 齋鹹構遞醖製夢築鹹鬱 ~ 鹹鏇築艱選鏇憲願顧夢) 更多	-	2021-03-30
				Placebo (Placebo)	窪願繭餘築艱獵壓繭遞(構網窪糧鏇網鹹網壓壓) = 廠壓餘觸餘壓衊廠積鏇夢願醖鏇淵壓齋鏇窪廠 (製窪糧襯範選夢鬱膚製, 鏇鬱衊憲壓夢積鏇膚鬱 ~ 壓壓願鹹範夢鑰範糧觸) 更多